Category: Markets
Published: 2026-06-28T19:54:47.000Z
Pfizer's stock recovered 2.6% on Friday after six consecutive declines, closing the week down 3.7%. This rebound occurred despite mixed news, including a failed lung cancer study but also an FDA label expansion for Ibrance, and an announcement of an incoming CFO. The company's dividend yield, which represents about 59% of its 2026 EPS target, is a key focus for investors amid Pfizer's significant R&D spending and recent management changes.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.